Arnatar Therapeutics_Life Sciences_YIJING CAPITAL

CN
Contact Us
CN

Home

Investment Portfolio

Frontier Technology

Life Sciences

About Us

Company Profile

Key Figures

Our Journey

Vision and Mission

Contact Us
Arnatar Therapeutics
Arnatar Therapeutics develops innovative oligonucleotide drugs. Its founding team comes from global oligonucleotide leader Ionis Pharmaceuticals. Its proprietary platform precisely upregulates or downregulates target gene expression, advancing therapies for genetic and metabolic diseases and other conditions
Arnatar Therapeutics
Back to List
We Look Forward to Hearing from You
Discovering talent, investing in the future, and growing with visionary entrepreneurs
Submit BP

Submit BP

Yijing Capital focuses on innovative companies in frontier technology, life sciences, and related fields. Please complete the basic project information and upload the latest version of your business plan (BP). Our investment team will evaluate the materials and contact projects that align with our investment focus.

Can't read it? Refresh
CAPTCHA

All submitted materials will be used solely for investment evaluation. We will strictly protect your business information.

Thank you for your trust in Yijing Capital.
We have received your business plan. After completing an initial evaluation, our investment team will contact projects that align with our investment focus. Due to the volume of submissions, we appreciate your understanding if you do not receive a follow-up. We wish your project every success!

OK

This website uses cookies
This website uses cookies to improve your experience while you navigate through the website. You can choose to opt-out if you wish. For more information, please refer to our 《Cookies》。